Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TBC has received/is pending research grants from Novartis, Genentech, Sanofi, and Regeneron; has received honoraria for speakers bureau from Genentech and Sanofi and has received consulting and advisory board fees from GSK, Novartis, Genentech, Sanofi, Regeneron, and AstraZeneca. AuB has received consulting and speaking fees from GSK independent of this activity, and consultant and speaking fees from AstraZeneca, Sanofi Genzyme, and Regeneron. ArB reports receiving personal fees, research grants, and non-financial support from GSK; personal fees and non-financial support from AstraZeneca and Novartis; research grants from MSD; research grant and personal fees from Actelion; and personal fees and non-financial support from Chiesi. PH and AS-K are employees of GSK and own stocks/shares. BH is a former employee of GSK and owns stocks/shares. SK has received research support from GSK and Sanofi; is a co-editor for a textbook for Springer, and is a Regent-at-Large for CHEST."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The editorial support provided for this review article was funded by GSK."